Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review

Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calcul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie, Shen, Yigen, Wang, Jiaoni, Xue, Yangjing, Liao, Lianming, Thapa, Saroj, Ji, Kangting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542281/
https://www.ncbi.nlm.nih.gov/pubmed/28515348
http://dx.doi.org/10.18632/oncotarget.17518
_version_ 1783254959640281088
author Wang, Jie
Shen, Yigen
Wang, Jiaoni
Xue, Yangjing
Liao, Lianming
Thapa, Saroj
Ji, Kangting
author_facet Wang, Jie
Shen, Yigen
Wang, Jiaoni
Xue, Yangjing
Liao, Lianming
Thapa, Saroj
Ji, Kangting
author_sort Wang, Jie
collection PubMed
description Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I(2) = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.
format Online
Article
Text
id pubmed-5542281
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55422812017-08-07 Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review Wang, Jie Shen, Yigen Wang, Jiaoni Xue, Yangjing Liao, Lianming Thapa, Saroj Ji, Kangting Oncotarget Meta-Analysis Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I(2) = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future. Impact Journals LLC 2017-04-29 /pmc/articles/PMC5542281/ /pubmed/28515348 http://dx.doi.org/10.18632/oncotarget.17518 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Meta-Analysis
Wang, Jie
Shen, Yigen
Wang, Jiaoni
Xue, Yangjing
Liao, Lianming
Thapa, Saroj
Ji, Kangting
Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title_full Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title_fullStr Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title_full_unstemmed Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title_short Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
title_sort relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542281/
https://www.ncbi.nlm.nih.gov/pubmed/28515348
http://dx.doi.org/10.18632/oncotarget.17518
work_keys_str_mv AT wangjie relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT shenyigen relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT wangjiaoni relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT xueyangjing relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT liaolianming relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT thapasaroj relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview
AT jikangting relationofphosphodiesterasetype5inhibitorsandmalignantmelanomaametaanalysisandsystematicreview

Ejemplares similares